Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was approved in 2006 ...

Adagene Inc. (NASDAQ:ADAG – Get Free Report) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 1,500 shares, a ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

Japanese drugmaker Chugai, which is majority owned by Roche, On Friday revealed that Zenyaku Kogyo has obtained regulatory ...

Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System AtrophyMASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the efficacy ...

Natixis Advisors LLC acquired a new position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) in the third ...

After hours: November 22 at 7:54 PM EST Loading Chart for IMAB ...

Although a non-profit entity with an explicit “public good” mandate, the BMC is currently operated as a contract manufacturer ...

Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- ...

Researchers have developed a new optical biosensor to detect the monkeypox virus. The biosensor can provide results in 20 minutes. The new technology ...

Dr. Pestell brings over three decades of in-depth research experience to the CytoDyn team, with robust expertise investigating novel drug products and therapies. He is currently the President of the ...

Fintel reports that on November 21, 2024, William Blair downgraded their outlook for Pyxis Oncology (NasdaqGS:PYXS) from ...